Bendamustine
💊 Brand Formulations & Prices
1 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesChronic Lymphocytic Leukemia (CLL)
: Bendamax is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.
Non-Hodgkin Lymphoma (NHL)
: Bendamaxis
... Read more
Chronic Lymphocytic Leukemia (CLL)
: Bendamax is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.
Non-Hodgkin Lymphoma (NHL)
: Bendamaxis indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Also indicated in Multiple myeloma.
Chronic lymphocytic leukaemia
: 100 mg/m
2
infused over 30-60 min on days 1 and 2 of a 28-day cycle for up to 6 cycles. For severe haematological or non-haematological toxicity: Reduce dose to 50 mg/m
2
on days 1 and 2 of each cycle. If severe haematological toxicity recurs, further reduce dose to 25 mg/m
2
on days 1 and 2 of each cycle. May consider dose re-escalation in subsequent cycles.
Multiple myeloma
: 120-150 mg/m
2
infused over 30-60 min on days 1 and 2 of a 28-day cycle. IV or oral prednisone may be given at a dose of 60 mg/m
2
on days 1-4 of the cycle.
Non-Hodgkin's lymphoma
: 120 mg/m
2
infused over 30-60 min on days 1 and 2 of a 21-day cycle for up to 8 cycles. For severe haematological or non-haematological toxicity: Reduced to 90 mg/m
2
on days 1 and 2 of each cycle. If severe toxicity recurs, further reduce dose to 60 mg/m
2
on days 1 and 2 of each cycle.
Patient with history of hypersensitivity (e.g. anaphylaxis and anaphylactoid reactions); jaundice, severe bone marrow suppression, low leukocyte or platelet count. Severe hepatic impairment. Major surgery <30 days prior to treatment.
Malignant and pre-malignant disease; pyrexia, nausea, vomiting, cough, headache, fatigue, diarrhoea, constipation, anorexia, wt decrease, rash, stomatitis, lymphopenia, anaemia, thrombocytopenia, leucopenia, neutropenia.
Mild to moderate hepatic and renal impairment. Pregnancy and lactation.
Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.